Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 268

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 268
---
 name from “Iris Acquisition Corp” to “Iris Parent Holding Corp.” as of the closing;

• Authorized Share Capital . Change the total number of shares of all classes of authorized capital stock from 300,000,000 shares of common stock, including 280,000,000 shares of Iris Class A Common Stock and 20,000,000 shares of Class B Common Stock, and 1,000,000 shares of preferred stock, to 501,000,000 shares of common stock, consisting of 500,000,000 shares of common stock and 1,000,000 shares of preferred stock;

• Dual-Class Capital Structure . Eliminate Class B Common Stock and any rights of holders thereof;

• Amendment . Provide that the affirmative vote of two-thirds of the total voting power of all the then outstanding shares of stock, shall be required to amend or repeal part (b) of Article IV, Article V, Article VI, Article VII, Article VIII, Article IX and Article X;

• Blank Check Company . Remove the provisions under Article IX (Business Combination Requirements; Existence) relating to Iris’s status as a blank check company; and

• Corporate Opportunity . Remove the provisions under Article X (Corporate Opportunity) relating to the application of the doctrine of corporate opportunity. Although Iris had previously waived the corporate opportunities doctrine, this did not impact Iris’s search for an acquisition target.

#### Reasons for the Amendments
The following is a summary of the reasons for the key changes effected by the Charter Proposal:

• Name Change . Changing the post-combination corporate name from “Iris Acquisition Corp” to “Iris Parent Holding Corp.” is desirable to reflect the Business Combination and to more closely align the name of the publicly traded entity with the name of the existing operating business;

• Authorized Share Capital . The pre-closing Iris Certificate of Incorporation (the “Pre-Closing Iris Certificate of Incorporation”) authorizes: (a) 300,000,000 shares of common stock, including 280,000,000 shares of Iris Class A Common Stock and 20,000,000 shares of Class B Common Stock and (b) 1,000,000 shares of preferred stock. This Proposal No. 4 provides that Liminatus will be authorized to issue 501,000,000 shares, consisting of 500,000,000 shares of common stock and 1,000,000 shares of preferred stock. Upon the elimination of the blank check provisions in the Pre-Closing Iris Certificate of Incorpor